供体特异性抗体检测技术的研究进展

匡国杰; 石炳毅; 肖漓

doi:10.3969/j.issn.1674-7445.2016.02.014

供体特异性抗体检测技术的研究进展

doi: 10.3969/j.issn.1674-7445.2016.02.014

100091 北京, 解放军第309医院器官移植研究室移植免疫室

基金项目:

国家高技术研究发展计划(863计划) 2012AA021002

详细信息

通讯作者:
石炳毅, Email:shibingyi@medmail.com.cn

中图分类号: R617;R392.4
计量
- 文章访问数: 222
- HTML全文浏览量: 151
- PDF下载量: 27
- 被引次数: 0
出版历程
- 收稿日期: 2015-12-20
- 网络出版日期: 2021-01-19
- 刊出日期: 2016-03-15

摘要

摘要: 抗体介导的排斥反应(AMR)是导致移植肾失功的首要原因, 而供者特异性抗体(DSA)是诊断移植肾体液性排斥反应的必要因素之一。因此, DSA检测方法的选择、技术的灵敏度和特异度对AMR的诊断和治疗有着重要的指导意义。随着器官移植外科手术水平的提高和新型免疫抑制剂的出现, 移植免疫学检测技术也在不断发展。本文对DSA的免疫学检测方法, 特别是应用Luminex-单抗原微珠法检测DSA的意义、技术优势及不足进行综述。
- 肾移植 /
- 供者特异性抗体 /
- 抗体介导的排斥反应 /
- Luminex-单抗原微珠法

HTML全文

参考文献(42)

[1]	Sellarés J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants[J].Am J Transplant, 2013, 13(4):971-983. doi: 10.1111/ajt.12150
[2]	Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report:inclusion of c4d-negative antibody-mediated rejection and antibody associated arterial lesions[J].Am J Transplant, 2014, 14(2):272-283. doi: 10.1111/ajt.12590
[3]	Sumitran-Holgersson S. HLA-specific alloantibodies and renal graft outcome[J]. Nephrol Dial Transplant, 2001, 16(5):897-904. doi: 10.1093/ndt/16.5.897
[4]	Terasaki PI, Mickey MR, Singal DP, et al. Serotyping for homotransplantation. XX. selection of recipients for cadaver donor transplants[J]. N Engl J Med, 1968, 279(20):1101-1103. doi: 10.1056/NEJM196811142792007
[5]	Terasaki PI. Humoral theory of transplantation[J]. Am J Transplant, 2003, 3(6):665-673. doi: 10.1034/j.1600-6143.2003.00135.x
[6]	Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation[J]. J Am Soc Nephrol, 2005, 16(9):2804-2812. doi: 10.1681/ASN.2004121130
[7]	Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation[J].J Am Soc Nephrol, 2010, 21(8):1398-1406. doi: 10.1681/ASN.2009101065
[8]	Han F, Lv R, Jin J, et al. Pre-transplant serum concentrations of anti-endothelial cell antibody in panel reactive antibody negative renal recipients and its impact on acute rejection[J]. Clin Chem Lab Med, 2009, 47(10):1265-1269. https://www.researchgate.net/publication/26809189_Pre-transplant_serum_concentrations_of_anti-endothelial_cell_antibody_in_panel_reactive_antibody_negative_renal_recipients_and_its_impact_on_acute_rejection
[9]	Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant[J]. Am J Transplant, 2012, 12(5):1157-1167. doi: 10.1111/j.1600-6143.2012.04013.x
[10]	Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival[J]. N Eng J Med, 2011, 365(4):318-326. doi: 10.1056/NEJMoa1012376
[11]	Zachary A, Reinsmoen NL. Quantifying HLA-specific antibodies in patients undergoing desensitization[J]. Curr Opin Organ Transplant, 2011, 16(4):410-415. doi: 10.1097/MOT.0b013e32834899b8
[12]	Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure[J]. Nat Rev Nephrol, 2012, 8(3):48-57. https://www.researchgate.net/publication/224052139_The_impact_of_donor-specific_anti-HLA_antibodies_on_late_kidney_allograft_failure
[13]	Otten HG, Verhaar MC, Borst HP, et al. Pretransplant donor-specific HLA class-Ⅰ and-Ⅱ antibodies are associated with an increased risk for kidney graft failure[J]. Am J Transplant, 2012, 12(6):1618-1623. doi: 10.1111/ajt.2012.12.issue-6
[14]	Caro-Oleas JL, González-Escribano MF, González-Roncero FM, et al. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation[J]. Nephrol Dial Transplant, 2012, 27(3):1231-1238. doi: 10.1093/ndt/gfr429
[15]	Mehra NK. The HLA complex in biology and medicine:a resource book[M]. New Delhi:Jaypee Brothers Medical Publishers, 2010.
[16]	Mehra NK, Siddiqui J, Baranwal A, et al. Clinical relevance of antibody development in renal transplantation[J]. Ann N Y Acad Sci, 2013, 1283:30-42. doi: 10.1111/nyas.12034
[17]	Spicer RA, Clayton PA, McTaggart SJ, et al. Patient and graft survival following kidney transplantation in recipients with cystinosis:a cohort study[J].Am J Kidney Dis, 2015, 65(1):172-173. doi: 10.1053/j.ajkd.2014.07.020
[18]	Pelletier RP, Adams PW, Hennessy PK, et al. Comparison of crossmatch results obtained by ELISA, flow cytometry, and conventional methodologies[J]. Hum Immunol, 1999, 60(9):855-861. doi: 10.1016/S0198-8859(99)00072-5
[19]	Zemmour J, Parham P. Distinctive polymorphism at the HLA-C locus:implications for the expression of HLA-C[J].J Exp Med, 1992, 176(4):937-950. doi: 10.1084/jem.176.4.937
[20]	Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome[J]. Transplantation, 2003, 75(7):1034-1040. http://d.wanfangdata.com.cn/NSTLQK_NSTL_QKJJ029931638.aspx
[21]	谢冲, 王国民. Luminex液相芯片的发展及应用[J].复旦学报(医学版), 2010, 37(2):241-244. http://www.cnki.com.cn/Article/CJFDTOTAL-SHYK201002027.htm Xie C, Wang GM. Development and application of Luminex liquichip[J]. Fudan Univ J(Med Sci), 2010, 37(2):241-244. http://www.cnki.com.cn/Article/CJFDTOTAL-SHYK201002027.htm
[22]	Bay JT, Garred P. Rapid bead based immunoassay for measurement of mannose-binding lectin[J]. Scand J Immunol, 2009, 69(6):570-575. doi: 10.1111/sji.2009.69.issue-6
[23]	Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor specific antibodies detected by Luminex posttransplant serve as biomarkers f or chronic rejection of renal allografts[J]. Transplantation, 2009, 87(10):1505-1513. doi: 10.1097/TP.0b013e3181a44206
[24]	Vaidya S, Partlow D, Susskind B, et al. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead Luminex assay[J]. Transplantation, 2006, 82(11):1524-1528. doi: 10.1097/01.tp.0000246311.43634.0a
[25]	Thammanichanond D, Ingsathit A, Mongkolsuk T, et al.Pre-transplant donor specific antibody and its clinical significance in kidney transplantation[J]. Asian Pac J Allergy Immunol, 2012, 30(1):48-54. https://www.ncbi.nlm.nih.gov/pubmed/22523907/
[26]	Aubert V, Venetz JP, Pantaleo G, et al. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically relevant[J]. Hum Immunol, 2009, 70(8):580-583. doi: 10.1016/j.humimm.2009.04.011
[27]	Malheiro J, Tafulo S, Dias L, et al. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation[J]. Transpl Immunol, 2015, 32(2):66-71. doi: 10.1016/j.trim.2015.01.002
[28]	Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts:a population-based study[J]. Lancet, 2013, 381(9863):313-319. doi: 10.1016/S0140-6736(12)61265-3
[29]	Marsh SG, WHO Nomenclature Committee for Factors of the HLA System. Nomenclature for factors of the HLA system, update Jane 2015[J]. Tissue Antigens, 2015, 86(3):234-237. doi: 10.1111/tan.2015.86.issue-3
[30]	Süsal C, Opelz G. Role and value of Luminex(®)-detected HLA antibodies before and after kidney transplantation[J]. Transfus Med Hemother, 2013, 40(3):190-195. doi: 10.1159/000351314
[31]	王庆华, 尚乐乐, 唐敏英, 等. Luminex技术与ELISA方法检测抗HLA抗体在肾移植急性排斥反应中的应用[J].中华器官移植杂志, 2013, 34(8):455-457. http://cpfd.cnki.com.cn/article/cpfdtotal-zjkx201311007911.htm Wang QH, Shang LL, Tang MY, et al. Comparison of Luminex vs. ELISA method to detect HLA antibodies in renal transplantation[J]. Chin J Organ Transplant, 2013, 34(8):455-457. http://cpfd.cnki.com.cn/article/cpfdtotal-zjkx201311007911.htm
[32]	Willicombe M, Brookes P, Sergeant R, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy[J]. Transplantation, 2012, 94(2):172-177. doi: 10.1097/TP.0b013e3182543950
[33]	DeVos JM, Gaber AO, Knight RJ, et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation[J].Kidney Int, 2012, 82(5):598-604. doi: 10.1038/ki.2012.190
[34]	Singh P, Colombe BW, Francos GC, et al. Acute humoral rejection in a zero mismatch deceased donor renal transplant due to an antibody to an HLA-DP alpha[J].Transplantation, 2010, 90(20):220-221. http://www.academia.edu/3780494/Acute_Humoral_Rejection_in_a_Zero_Mismatch_Deceased_Donor_Renal_Transplant_Due_to_an_Antibody_to_an_HLA-DP
[35]	Worthington JE, Robson AJ, Sheldon S, et al. A comparison of enzyme-1inked immunoabsorbent assays and flow cytometry techniques for the detection of HLA specific antibodies[J]. Hum Immunol, 2001, 62(10):1178-1184. doi: 10.1016/S0198-8859(01)00282-8
[36]	Haarberg KM, Tambur AR. Detection of donor-specific antibodies in kidney transplantation[J]. Br Med Bull, 2014, 110(1):23-34. doi: 10.1093/bmb/ldu005
[37]	Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival[J]. N Engl J Med, 2013, 369(13):1215-1226. doi: 10.1056/NEJMoa1302506
[38]	Jaini R, Kaur G, Mehra NK.Heterogeneity of HLA-DRB104 and its associated haplotypes in the North Indian population[J]. Hum Immunol, 2002, 63(1):24-29. doi: 10.1016/S0198-8859(01)00352-4
[39]	Filippone EJ, Farber JL. Humoral immune response and allograft function in kidney transplantion[J]. Am J Kidney Dis, 2015, 66(2):337-347. doi: 10.1053/j.ajkd.2015.03.033
[40]	Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy[J]. Transplantation, 2008, 86(6):820-825. doi: 10.1097/TP.0b013e3181856f98
[41]	Lucas JG, Co JP, Nwaogwugwu UT, et al. Antibody-mediated rejection in kidney transplantation:an update[J]. Expert Opin Pharmacother, 2011, 12(4):579-592. doi: 10.1517/14656566.2011.525219
[42]	Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop[J].Am J Transplant, 2011, 11(5):896-906. doi: 10.1111/j.1600-6143.2011.03525.x